ИЗМЕНЕНИЯ СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЫ У ДЕТЕЙ, ПЕРЕНЕСШИХ COVID-19

Бобомуратов Т.А Ташкентская медицинская академия

Каримова Н.А. Ташкентская медицинская академия

Резюме

В статье рассматриваются вопросы этиопатогенеза COVID-19 у детей, развитие детского мультисистемного воспалительного синдрома у инфицированных детей, факторы риска развития поражения миокарда, патогенез и вопросы диагностики сердечно-сосудистых осложнений.

Ключевые слова: COVID-19, дети, детский мультисистемный воспалительный синдром, поражение миокарда, диагностика.

Первая страница
112

Последняя страница
117

Для цитирования

Бобомуратов Т.А  Каримова Н.А. ИЗМЕНЕНИЯ СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЫ У ДЕТЕЙ, ПЕРЕНЕСШИХ COVID-19 // Евразийский вестник педиатрии. — 2021; 2 (9): 112-117. https://cutt.ly/QEsEjU5

Литература

  1. 1. Abaturov A.E., Agafonova E.A., Krivusha E.L., Nikulina A.A. Pathogenesis of COVID-19. // Zdorov’e Rebenka. — 2020. — T. 15 (2). — S. 133-144. doi: 10.22141 / 2224-0551.15.1.2020.200598.
  2. 2. Alimova Kh.P., Rakhmanova D.I., Mardanova Kh.A. and other Features of the clinical course of coronavirus infection in children // Infection, immunity and pharmacology. — 2021.- No. 4.- P.34-39.
  3. 3. Zaplatnikov A.L., Svintsitskaya G.I. COVID-19 // GRM. — 2020.- No. 1.- P.1-3.
  4. 4. Ifran O., Tang K., Arin M., Bhutta Z.A. Epidemiology, characteristics and impact on children, adolescents and pregnant women // Pediatric Pharmacology. — 2020.- T.17 (4) .- S.352-359.
  5. 5. Kantemirova MG, Novikova Yu.Yu., Ovsyannikov D.Yu. et al. Children’s multisystem inflammatory syndrome associated with novel coronavirus infection (COVID-19): current information and clinical observation. // Pediatric Pharmacology. — 2020.- T.17 (3) .- S.219-229. doi: 10.15690 / pf.v17i3.2126
  6. 6. Kubanov A.A., Deryabin D.G. A new look at the pathogenesis of COVID-19: the disease is a generalized viral vasculitis, and the resulting damage to the lung tissue is a variant of angiogenic pulmonary edema. // Bulletin of the Russian Academy of Medical Sciences. — 2020.- T.75 (2). doi: 10.15690 / vramn1347.https: //vestnikramn.spr-journal.ru/jour/article/view/1347/ 1220
  7. 7. Sabirov J.R., Khusanov A.M., Shamsutdinova M.I. and others. Health care in the era of a pandemic through the prism of time: international experience and achievements in the fight against COVID-19 // Infection, immunity and pharmacology. — 2021.- No. 4.- P.5-15.
  8. 8. Safina A.P., Zakirov I.I., Lutfullin I.Ya., Volianyuk E.V., Daminova M.A. COVID-19 in childhood: what is the accumulated experience? // Russian Herald of Perinatology and Pediatrics. — 2020.- T. 65 (5) .- S. 193-197.
  9. 9. Sushentseva N.N., Popov O.S., Apalko S.V. et al. Biobank COVID-19: features of the cytokine profile // Cardiovascular therapy and prevention. — 2020.- T.19 (6) .- S. 191-195.
  10. 10. Turabova N.R., Shamsutdinova M.I. Potential plots of the development of the immune response to the new type of coronavirus SARS-CoV-2 // Infection, Immunity and Pharmacology. — 2021.- No. 4.- P. 99-107.
  11. 11. Khidoyatova M.R., Kayumov U.K., Inoyatova F.Kh. and others. Indicators of the hemostasis system in patients with cardiovascular diseases against the background of COVID-19 // Infection, immunity and pharmacology. — 2021.- No. 4.- P.116-119.
  12. 12. Shamsheva O.V. New coronavirus COVID-19 (SARS-CoV-2) // Children’s infections. — 2020.- T.19 (1) .- S.5-6.
  13. 13. Abduvaliev A.R., Inoyatova F.Kh., Mirkomilov E.M. A method of inhibiting t-helper 2 cells to prevent lung fibrosis that develops as a result of atypical pneumonia in COVID-19 // Proceeding of Global Congress of Contemporary Study- A Multidisciplinary International Scientific Conference Hosted from Pune, M.S. India.- P.182-187. www.econferenceglobe.com
  14. 14. Belhadjer Z, Méot M, Bajolle F et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. // Circulation.- 2020.-Vol.17.- P. Epub ahead of print. doi: 10.1161/CIRCULATIONAHA.120.048360.
  15. 15. CDC COVID-19 Response Team. Coronavirus disease 2019 in children. United States, February 12-April 2, 2020. MMWR Morb.Mortal Wkly Rep. 2020 Apr 6. http://dx.doi.org/10.15585/mmwr.mm6914e4.
  16. 16. Cross L.M., Matthay M.A. Biomarkers in acute lung injury // Crit Care Clin.- 2011.- Vol.27(2).- P.355-377.
  17. 17. Hennon TR, Penque MD, Abdul-Aziz R, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. // Prog Pediatr Cardiol.- 2020.-Vol.23:101232. Epub ahead of print. doi: 10.1016/j.ppedcard.2020.101232.
  18. 18. Ji L.H., Zhao R., Matalon S., Matthay M.A. Elevated plasminogen as a common risk factor for COVID-19 susceptibility // Physiological Reviews.- 2020.- Vol.100(3).- P.1065-1075.
  19. 19. Lu R., Zhao X., Li J, et al. Genomic charactterisation and epidemiology of 2019 novel cjrjnavirus: Implications for virus origins and receptor binding. //Lancet.- 2020.- Vol.395.- P.565-574.
  20. 20. United States Centers for Disease Control and Prevention. Cases in the US. https://coronavirus/2019-ncov/cases-updates/cases-in-uz.html

Статья доступна ниже :

Скачать PDF